Literature DB >> 12069540

Lysosomal disorders.

J E Wraith1.   

Abstract

Although most lysosomal storage disorders present in infancy or early childhood with a progressive condition often associated with dysmorphism, considerable genetic heterogeneity exists resulting in a range of illnesses that can include a dramatic neonatal presentation. Whilst some conditions present with a characteristic neonatal phenotype (e.g. Niemann-Pick disease type C), the remainder present in a nonspecific way often with non-immune hydrops fetalis. Diagnosis can be helped by appropriate radiological studies and, in some patients, evidence of the storage phenomena can be seen in peripheral blood smears or bone marrow aspirates. Unfortunately, for the majority of affected patients no effective, curative, treatment is possible. New developments in therapy including enzyme replacement therapy and substrate deprivation may improve prognosis in some disorders. It is important to establish an accurate diagnosis, as prenatal testing can then be offered in future pregnancies. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12069540     DOI: 10.1053/siny.2001.0088

Source DB:  PubMed          Journal:  Semin Neonatol        ISSN: 1084-2756


  43 in total

Review 1.  Lysosomal storage disorders in the newborn.

Authors:  Orna Staretz-Chacham; Tess C Lang; Mary E LaMarca; Donna Krasnewich; Ellen Sidransky
Journal:  Pediatrics       Date:  2009-04       Impact factor: 7.124

Review 2.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 3.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

Review 4.  Laboratory diagnostic approaches in metabolic disorders.

Authors:  Ruben Bonilla Guerrero; Denise Salazar; Pranoot Tanpaiboon
Journal:  Ann Transl Med       Date:  2018-12

Review 5.  New strategies for enzyme replacement therapy for lysosomal storage diseases.

Authors:  Jeffrey H Grubb; Carole Vogler; William S Sly
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

6.  Quality of life of brazilian patients with Gaucher disease and fabry disease.

Authors:  Fabiane Lopes Oliveira; Taciane Alegra; Alicia Dornelles; Bárbara Corrêa Krug; Cristina B O Netto; Neusa Sica da Rocha; Paulo D Picon; Ida Vanessa D Schwartz
Journal:  JIMD Rep       Date:  2012-04-18

7.  Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

Authors:  David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

8.  Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.

Authors:  Jonathan H LeBowitz; Jeffrey H Grubb; John A Maga; Deborah H Schmiel; Carole Vogler; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

Review 9.  Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.

Authors:  Louise L C Pinto; Taiane A Vieira; Roberto Giugliani; Ida V D Schwartz
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

10.  Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.

Authors:  Marcelina Malinowska; Fiona L Wilkinson; Kia J Langford-Smith; Alex Langford-Smith; Jillian R Brown; Brett E Crawford; Marie T Vanier; Grzegorz Grynkiewicz; Rob F Wynn; J Ed Wraith; Grzegorz Wegrzyn; Brian W Bigger
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.